Lymphoma
Conditions
Keywords
lymphoma
Brief summary
Study to test feasibility and efficacy of T-replete Bone Marrow (BM), infused after a RIC regimen and post-transplantation Cyclophosphamide (Cy), in patients with poor prognosis lymphomas.
Detailed description
Allogeneic stem cell transplantation (ALLO) is the treatment of choice for many hematological diseases. However, HLA identical donor (sibling or unrelated) is available for 50-60% of patients and alternative donors are needed. Haploidentical donors have been used for many years, mostly after extensive T-cell depletion of peripheral stem cell, to avoid Graft Versus Host Disease (GVHD). Recently, promising data have been reported with haploidentical transplantation using T-replete bone marrow (BM) and high-dose cyclophosphamide (Cy) post-transplantation. However, the conditioning regimen did not contain drugs active against hemopathies, enhancing the relapse risk. In this study, the investigators want to test the feasibility and efficacy of T-replete BM, infused after a RIC regimen and post-transplantation Cy, in patients with poor prognosis lymphoproliferative diseases. The RIC regimen consisted of modified regimen used in different studies conducted in Italy on behalf GITMO.
Interventions
DRUGThiotepa
Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
DRUGFludarabine
Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows: CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day
DRUGCyclophosphamide
Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5. Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW) Cyclophosphamide \[50 mg/kg/day IBW\] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume).
Sponsors
Istituto Clinico Humanitas
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Signed and dated IEC-approved informed consent * Age ≥ 18-70 years old. * Performance Status Karnofsky ≥ 80% (see appendix B) * HLA typing will be performed at high resolution (allele level) for the HLA-A, HLA -B, HLA Cw, HLA-DRB1, and HLA-DQB1 loci. A minimum match of 5/10 is required. An unrelated donor search is not required for a patient to be eligible for this protocol if the clinical situation dictates an urgent transplant. * The donor and recipient must be identical, as determined by high resolution typing, at least one allele of each of the following genetic loci: HLA-A, HLA-B, HLA-Cw, HLA-DRB1, and HLA-DQB1. * Patients with lymphoma (any histology) relapsed after high dose chemotherapy and in partial remission, complete remission or stable disease after the last CT line. 1. Hodgkin's lymphoma: Patients refractory to at least 2 CT lines, and included in tandem auto-allo program 2. Diffuse large B cell lymphoma: Refractory to second line salvage chemotherapy (patients in partial remission, stable disease or progressive). These patients have to be in partial remission, complete remission or stable disease after one o more further CT line. 3. Peripheral T cell lymphoma: Patients failing to achieve a complete remission after first line CT. 4. Low grade lymphomas (follicular and non follicular: Patients refractory to rituximab containing regimens. Patients relapsing after at least 2 lines CT. The duration of remission should be \< 1 year. 5. Chronic lymphatic leukemia: Patients with refractory or relapsing (response duration \< 1 year) disease after R-Fludarabine CT 6. Mantle cell lymphoma: Patients relapsing or refractory after first line conventional CT. * Absence of HLA identical sibling and 10/10 unrelated donor * Patients with adequate physical function as measured by: Cardiac: Left ventricular ejection fraction at rest must be ≥ 40% Hepatic: Bilirubin ≤ 2.5 mg/dL; and ALT, AST, and Alkaline Phosphatase ≤ 5 x ULN. Renal: Creatinine clearance or GFR ≥ 50 mL/min/1.73 m2. Pulmonary: FEV1, FVC, DLCO ≥ 50% predicted (corrected for hemoglobin); if unable to perform pulmonary function tests, then O2 saturation ≥ 92% on room air.
Exclusion criteria
* Presence of HLA-matched, related donor (HLA-A, -B, -DRB1) * Presence of matched unrelated donor (10/10), available on time. * Pregnancy or breast-feeding. * Evidence of HIV infection or known HIV positive serology. * Current uncontrolled bacterial, viral or fungal infection * Evidence of progression of clinical symptoms or radiologic findings. * Prior allogeneic hematopoietic stem cell transplant. * Central Nervous System (CNS) lymphoma localization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Procedure activity | 1 year | 1-year Progression Free Survival (PFS) to evaluate the activity of the procedure (taking into account an excess of toxicity). It is assumed that at 1-year a proportion of patients progression free of 20% or lower will be considered to be clinically unworthy, whereas a proportion of 40% or higher will be assumed to be of potential interest. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Platelets recovery | 1 year | Platelets will be measured at different time points of increasing lenght up to 1 year after transplant and then if clinically indicated |
| Incidence of graft failure | 1 year | — |
| Cumulative incidence of acute and chronic GVHD | 1 year | — |
| Neutrophils recovery | 1 year | Neutrophils will be measured at different time points of increasing lenght up to 1 year after transplant and then if clinically indicated |
| Cumulative incidence of relapse/progression | 1 year | — |
| Treatment related mortality (TRM) | 1 year | — |
| Immunological reconstitution | 1 year | T, B and NK subsets will be analysed in deep using cytofluorimetry and functional tests. |
| Incidence of infections | 1 year | Possible infections will be monitored for a time period of 1 year post-transplantation and then if clinically required |
Countries
Italy
Contacts
Primary ContactLuca Castagna, MD
Outcome results
None listed